13F Holdings
中文EN

NSPR InspireMD, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1433607 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY35.8%
TTM net income YoY-7.2%
TTM EPS YoY30.5%
Revenue 3-yr CAGR24.5%
Net income 3-yr CAGR—

Margins

Gross margin12.6%
Operating margin-477.8%
Net margin-469.1%
FCF margin-420.3%
EBITDA margin4,031.1%

Returns

ROE-115.4%
ROA-88.4%
ROIC (approx.)-2,478.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets35.2%
Debt / equity0.00x
Current ratio2.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue11.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$8.98M$7.01M$6.21M$5.17M$4.50M
Cost of revenue$6.33M$5.50M$4.40M$4.05M$3.74M
Gross profit$2.65M$1.51M$1.81M$1.12M$754,000
R&D expense$15.00M$13.63M$7.98M$7.81M$5.16M
SG&A expense$20.71M$15.31M$11.10M$8.36M$7.41M
Operating income-$49.61M-$33.50M-$21.14M-$18.71M-$14.72M
Pretax income-$48.72M-$31.95M-$19.85M-$18.46M-$14.87M
Income tax$63,000$59,000$65,000$28,000$45,000
Net income-$48.79M-$32.01M-$19.92M-$18.49M-$14.92M
EBITDA$426.39M$246.50M$210.86M$169.29M-$14.55M
EPS (basic)-0.76-0.76-0.82-2.35-2.03
EPS (diluted)-0.76-0.76-0.82-2.35-2.03
Weighted avg. shares (diluted)64.33M41.93M24.27M7.87M7.35M
Balance sheet
Cash & equivalents$8.94M$18.92M$9.64M$4.63M$12.00M
Short-term investments$45.27M$15.72M$29.38M——
Receivables$2.17M$1.57M$1.80M$1.03M$1.22M
Inventory$3.40M$2.57M$2.11M$1.62M$1.14M
Current assets$61.47M$40.52M$44.16M$21.33M$37.09M
PP&E, net$3.58M$2.37M$1.06M$917,000$632,000
Total assets$69.40M$46.81M$47.64M$24.65M$39.71M
Current liabilities$10.71M$7.68M$6.02M$5.07M$4.35M
Total liabilities$14.20M$10.72M$8.14M$7.26M$6.18M
Shareholders' equity$55.20M$36.09M$39.50M$17.39M$33.53M
Shares outstanding43.53M26.61M21.84M8.33M8.30M
Cash flow statement
Operating cash flow-$35.10M-$21.87M-$16.38M-$15.54M-$13.21M
Capital expenditure$1.66M$1.40M$381,000$473,000$344,000
Free cash flow-$36.77M-$23.27M-$16.76M-$16.02M-$13.55M
Investing cash flow-$30.56M$12.64M-$16.09M$8.44M-$22.46M
Financing cash flow$55.57M$18.45M$37.53M-$140,000$35.03M
Depreciation & amortization$476.00M$280.00M$232.00M$188.00M$161,000
Stock-based compensation$12.33M$10.14M$4.49M$2.35M$1.58M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.